Brokerage firm Cowen & Co. Downgrades its rating on AMAG Pharmaceuticals(AMAG). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by Cowen & Co. was issued on Feb 3, 2017.
In a different note, On Jan 9, 2017, Raymond James said it Downgrades its rating on AMAG Pharmaceuticals. The shares have been rated ‘Underperform’ by the firm. Janney Capital said it Initiates Coverage On AMAG Pharmaceuticals, according to a research note issued on Jan 3, 2017. In the research note, the firm Announces the price-target to $45 per share. The shares have been rated ‘Buy’ by the firm. Cantor Fitzgerald said it Initiates Coverage On AMAG Pharmaceuticals, according to a research note issued on Dec 16, 2016. In the research note, the firm Announces the price-target to $33 per share. The shares have been rated ‘Neutral’ by the firm.
AMAG Pharmaceuticals (AMAG) made into the market gainers list on Tuesdays trading session with the shares advancing 0.45% or 0.1 points. Due to strong positive momentum, the stock ended at $22.15, which is also near the day’s high of $22.35. The stock began the session at $22.15 and the volume stood at 6,82,254 shares. The 52-week high of the shares is $36.825 and the 52 week low is $17.92. The company has a current market capitalization of $758 M and it has 3,42,09,743 shares in outstanding.
AMAG Pharmaceuticals(AMAG) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $132.47M. Analysts had an estimated revenue of $128.70M. Earnings per share were $1.45. Analysts had estimated an EPS of $1.20.
Several Insider Transactions has been reported to the SEC. On Oct 20, 2016, Julie Krop (SVP Clinical & Regulatory, CMO) sold 4,938 shares at $24.80 per share price.Also, On Nov 10, 2015, John A. Fallon (director) purchased 3,230 shares at $31.20 per share price.On Oct 2, 2015, William K Heiden (CEO) sold 2,000 shares at $39.69 per share price, according to the Form-4 filing with the securities and exchange commission.
AMAG Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on maternal health anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection) Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers such as those caused by oral surgery or ill-fitting dentures or braces.